key: cord-0282860-chf9hxip authors: Ostropolets, A.; Ryan, P. B.; Schuemie, M. J.; Hripcsak, G. title: Differential anchoring effects of vaccination comparator selection: characterizing a potential bias due to healthcare utilization in COVID-19 versus influenza date: 2021-10-11 journal: nan DOI: 10.1101/2021.10.07.21264711 sha: 2065cecaa3289e016ab286fa19a7ed39e9cf3396 doc_id: 282860 cord_uid: chf9hxip Introduction Observational data enables large-scale vaccine safety surveillance but requires careful evaluation of potential sources of bias. One potential source of bias is an index date selection procedure for the unvaccinated cohort or unvaccinated comparison time. Here, we evaluate different index date selection procedures for two vaccines: COVID-19 and influenza. Methods For each vaccine, we extracted patient baseline characteristics on the index date and up to 450 days prior and then compared them to the characteristics of the unvaccinated patients indexed on an arbitrary date or indexed on a date of a visit. Additionally, we compared vaccinated patients indexed on the date of vaccination and the same patients indexed on a prior date or visit. Results COVID-19 vaccination and influenza vaccination differ drastically from each other in terms of populations vaccinated and their status on the day of vaccination. When compared to indexing on a visit in unvaccinated population, influenza vaccination had markedly higher covariate proportions and COVID-19 vaccination had lower proportions of most covariates on the index date. In contrast, COVID-19 vaccination had similar covariate proportions when compared to an arbitrary date. These effects attenuated but were still present with a longer lookback period. The effect of day 0 was present even when patients served as their own controls. Conclusion Patient baseline characteristics are sensitive to the choice of the index date. In vaccine safety studies, unexposed index event should represent vaccination settings. Study designs previously used to assess influenza vaccination must be reassessed for COVID-19 to account for a potentially healthier population and lack of medical activity on the day of vaccination. Observational data enables large-scale vaccine safety surveillance but requires careful evaluation of potential sources of bias. One potential source of bias is an index date selection procedure for the unvaccinated cohort or unvaccinated comparison time. Here, we evaluate different index date selection procedures for two vaccines: COVID-19 and influenza. For each vaccine, we extracted patient baseline characteristics on the index date and up to 450 days prior and then compared them to the characteristics of the unvaccinated patients indexed on an arbitrary date or indexed on a date of a visit. Additionally, we compared vaccinated patients indexed on the date of vaccination and the same patients indexed on a prior date or visit. populations vaccinated and their status on the day of vaccination. When compared to indexing on a visit in unvaccinated population, influenza vaccination had markedly higher covariate proportions and COVID-19 vaccination had lower proportions of most covariates on the index date. In contrast, COVID-19 vaccination had similar covariate proportions when compared to an arbitrary date. These effects attenuated but were still present with a longer lookback period. The effect of day 0 was present even when patients served as their own controls. Patient baseline characteristics are sensitive to the choice of the index date. In vaccine safety studies, unexposed index event should represent vaccination settings. Study designs previously used to assess influenza vaccination must be reassessed for COVID-19 to account for a potentially healthier population and lack of medical activity on the day of vaccination. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The world is faced with a deadly pandemic at a time of incredible technology such that new vaccines can be produced in a fraction of the previous development time and at a scale that can potentially vaccinate the entire human population. This brings new challenges in using observational data to evaluate vaccine safety, where pressure to vaccinate quickly to prevent more deaths and more viral variants reduces time to carry out studies [1] . This time pressure affects not just the collection of data for research but even the time it takes to develop and validate evaluation methods. We therefore rely on methods developed and validated in previous pandemics and seasonal infectious diseases, with influenza being an important example [2] [3] [4] [5] . COVID-19 vaccination has been unlike any other in history. The target vaccination group has shifted from the elderly and those with comorbidities in the early phases of vaccination to everyone including the healthy young [6] , with some nations already vaccinating the majority of their populations [7] . COVID-19 vaccines are delivered in a wide variety of settings, from popup centers unconnected to health care delivery to inpatient facilities on hospital discharge. Other vaccines like those for influenza have a different delivery. They are often administered to specific vulnerable populations such as pregnant women, patients at high risk of complications or children, and are often given during health care visits [8] [9] [10] . The unique properties of COVID-19 vaccination may require adjusting study designs previously used for influenza vaccination, specifically the selection of a comparator cohort or an unvaccinated comparison time in cohort and self-controlled studies. While for the vaccinated group, the index date -vaccination -is clearly defined, selection of the index date for the unexposed comparator group is more complex. The selection procedure (which we have termed "anchoring") may itself influence the results of a study and induce bias in the analysis. For example, in studies of background rates of adverse events, patients indexed on an arbitrary date were shown to have lower incidence of adverse events compared to the same patients indexed on a visit [11] . Ideally, the index date in the unexposed group should be chosen based on the vaccination settings to reliably serve as a counterfactual. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint Here, we evaluate two alternative selection procedures based on how vaccines are administeredcoupled or decoupled to another healthcare encounter. We compare these approaches for two vaccines: influenza and COVID-19. We studied two types of vaccination: influenza vaccine administered during 2017 -2018 and COVID-19 vaccine administered during 2020 -2021. For each vaccine, we mimicked two study designs. The first design (Figure 1 , A) corresponds to a cohort method, where the target group was vaccinated patients, and the comparator group was unvaccinated patients. The index date for the target group was the date of vaccination; for the comparator it was (a) a date selected from the unvaccinated patient's history (not necessarily with any medical event) such that it matched the index date of one of the target group participants or (b) a visit matched to the index date of one of the target group participants. Patients in each target and comparator pair were matched on age and sex. The second design corresponds to a self-controlled design (case-crossover design) [12] where the cases were the vaccinated patients indexed (or "anchored") on the day of vaccination and the controls were the same patients indexed on an arbitrary date or a visit within 180-450 days prior to the vaccination date. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint For each group, we collected patient baseline characteristics (covariates) recorded within five time intervals: at the index date (day 0), at the day before the index date (day -1), from 30 to 1 day prior to the index date (short term baseline covariates), from 180 to 31 day prior to the index date (medium term baseline covariates) and from 450 to 181 day prior to the index date (long term baseline covariates). Baseline covariates included all conditions, procedures, measurements and drug groups available in patient records within a specified time interval. For each covariate, we calculated covariate proportion, which is the proportion of patients with a covariate recorded in their electronic health record within a given time interval. We conducted the analysis on two electronic health record data sources: Columbia University Record Dataset (Optum EHR). Optum EHR's data comprises medical record data from 87 million patients and includes clinical information, inclusive of prescriptions as prescribed and administered, lab results, vital signs, body measurements, diagnoses, procedures, and information derived from clinical notes using natural language processing. CUMC EHR gathers data from the clinical data warehouse of NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, based on its current and previous electronic health record x ts rd . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint systems, with data spanning over 30 years and including over 6 million patients. All data sources were mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) [13] . The OMOP CDM provides a homogeneous format for healthcare data and standardization of underlying clinical coding systems that thus enables analysis code to be shared across participating datasets in the network. On the index date (day of vaccination = day 0), the influenza vaccinated population had markedly higher proportion of most covariates than an arbitrary date in the comparison group As opposed to the influenza vaccinated population, the difference in covariate proportion between COVID-19 vaccinated population and unvaccinated population indexed on an arbitrary date was moderate. We observed that COVID-19 vaccination was associated with a visit in 2.7% % . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. Here we compared vaccinated patients indexed on the vaccination date to the same patients indexed on a date or visit within a year prior as we would do in a self-controlled study. We observed that the date of influenza vaccination tended to have a higher proportion of covariates compared to an arbitrary date within a year prior (Figure 3 , first column) and even higher compared to an arbitrary visit within a year prior. Patients indexed on the date of vaccination were more likely to have antecedent healthcare encounters, conditions and laboratory tests within a year prior to the vaccination date than within a year prior to their previous visits (Figure 3 , C and D). For comparison with an arbitrary date, we observed a mixed effect: in Optum EHR, vaccinated patients had more events preceding their vaccination while in CUMC they had fewer events. Nevertheless, in both data sources the difference between covariate proportions was larger in magnitude when compared to an arbitrary date than when compared to an arbitrary visit. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint The COVID-19 vaccinated population showed a markedly lower proportion of covariates on the day of vaccination compared to a visit or an arbitrary date within a year prior to vaccination. The difference was attenuated with a longer lookback period: COVID-19 vaccinated patients had fewer healthcare events within a year prior to their vaccination compared to their previous history. The difference was less pronounced when compared to an arbitrary date, which, again, points out that an arbitrary date is a better counterfactual for COVID-19 vaccination than an arbitrary visit. We find that COVID-19 vaccination and influenza vaccination differ drastically from each other, with the proportion of most covariates much higher on the date of vaccination in the influenza group than the COVID-19 group. The results from looking back 31 to 180 days and 181 to 450 days before the vaccination (or index date) may be related to differences in the populations. Persons vaccinated for influenza appear to have more comorbidities and past procedures and measurements than the average population, even after adjusting for age and sex, and persons vaccinated for COVID-19 appear to have a lower proportion of most medical covariates than the average population after adjusting for age and sex. This may be explained if influenza vaccination is targeted to sicker populations on average and if COVID-19 is targeted to the general public, which is healthier on average than those in our electronic health records [8, 10] . The drastic effects on day 0-i.e., the day of vaccination and its comparison-are likely related to the context in which the vaccination is given. If the comparison is an arbitrary date in the person's record, then influenza vaccination has markedly higher covariate proportions, reflecting the association of the vaccination with a healthcare encounter. Moreover, such a trend (not observed for COVID-19 vaccine) was present even when comparing the date of influenza vaccination to the prior patient visits. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint The first implication of these results is that, when comparing vaccinated to unvaccinated patients or time, the anchoring event for unvaccinated comparator must be selected carefully. Previous research acknowledged that comparing unexposed and exposed patients in the context of vaccine safety and effectiveness surveillance may lead to between-person confounding due to noncomparable groups [14] . For example, as noted before for influenza, vaccinated and unvaccinated patients differ in co-morbidity prevalence [15] . Nevertheless, even in the same population, the choice of the index date or event influences both baseline covariates and incidence rates of conditions following the index date. For COVID-19 vaccination, it appears that the comparison should not be purposely anchored on a health care visit unless it is a relevant vaccination subgroup (e.g., those vaccinated at hospital discharge). Adjusting for confounding will be extremely important, as it appears unlikely that a comparison can be chosen perfectly, although the comparisons between the same participants looking a year prior led to the best equivalency for both influenza and COVID-19. Moreover, the difference in patient characteristics require robust selection of covariates for a propensity score model or outcome model as opposed to the current exposed vs unexposed COVID-19 vaccine cohort studies, which only use a limited subset of covariates in their propensity score model [16] . Alternatively, this may argue for a self-controlled study design [17] , which mitigates the difference in patient characteristics. However, this design is also sensitive to anchoring (which is what happens on day 0 and around it) and carries other challenges such as accounting for differences in COVID-19 risk over time. This study has implications beyond using covariates for confounding adjustment. The day 0 results have direct implications for analyses of acute side effects like anaphylaxis that include day 0 because the side effect often occurs immediately. Any study of such short-term effects must directly account for anchoring to the context in which the vaccination is given. Furthermore, studies that compare effectiveness or safety among vaccines must account for differences in populations and in vaccination context. For example, single-dose vaccines may be given preferentially to sicker patients who are unable to return for a second dose, such as those being discharged from the hospital. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint COVID-19 vaccines: where we stand and challenges ahead Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza. medRxiv Cold Spring Harbor Laboratory Preprints The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine -United States COVID-19) Vaccinations -Statistics and Research Our World in Data A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza Higher Than Expected in Hospitalized Adults Hou PC, others. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel-33 US sites Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers Design considerations in an active medical product safety monitoring system: DESIGN CONSIDERATIONS FOR ACTIVE MONITORING Lifestyle, socioeconomic characteristics, and medical history of elderly persons who receive seasonal influenza vaccination in a tax-supported healthcare system FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21264711 doi: medRxiv preprint